Hermetica Superfood Encyclopedia
The Short Answer
Porphyran is a β-type sulfated hetero-rhamno-galactan-pyranose (~151.6 kDa) and its degraded oligo-form (OP145, ~2.1 kDa) that exerts anti-inflammatory, antioxidant, and lipid-lowering activities by modulating MAPK signaling, suppressing NO and ROS production, and inhibiting lipid accumulation in hepatocytes. Preclinical in vitro evidence shows the associated peptide PPY1 (532 Da) significantly reduces LPS-induced NO and ROS in RAW 264.7 macrophages at 250–1000 ng/ml (P<0.05), while purified porphyran (PPYP) demonstrates non-cytotoxic lipid-lowering effects in HepG2 cells up to 200 µg/ml; no human clinical trial data are currently available.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordporphyran benefits
Porphyran — botanical close-up
Health Benefits
**Anti-inflammatory Activity**
The PPY1 peptide (K-A-Q-A-D, 532 Da) derived from Pyropia yezoensis protein suppresses LPS-induced inflammation in RAW 264.7 macrophages by dose-dependently reducing nitric oxide (NO) and reactive oxygen species (ROS) production at 250–1000 ng/ml, with significant effects at P<0.05, without cytotoxicity.
**Antioxidant Protection**
Sulfated galactose and 3,6-anhydro-L-galactose units within the porphyran backbone contribute to free radical scavenging capacity; the high sulfate content (27.76% in OP145) is structurally associated with redox-modulating potential observed in in vitro assays.
**Lipid-Lowering and Hepatoprotective Effects**
Purified porphyran (PPYP) reduces lipid accumulation in palmitic acid (PA)-induced HepG2 hepatocyte cells at concentrations up to 200 µg/ml, with no observed cytotoxicity, suggesting a potential role in managing hepatic steatosis-related conditions.
**Potential Antiviral Properties**: Oligo-porphyran OP145 (mean Mw 2
1 kDa, composed predominantly of →3)-β-D-Gal-(1→4)-α-L-Gal(6S) repeating units) has been investigated for inhibition of SARS-CoV-2 spike protein–ACE2 receptor interaction, representing a structurally targeted antiviral mechanism common to sulfated oligosaccharides.
**Immunomodulatory Potential**
Traditional pharmacological records and preliminary research attribute immunomodulatory activity to porphyran, consistent with the behavior of other marine sulfated polysaccharides that interact with pattern recognition receptors and cytokine regulatory networks.
**Antitumor Research Interest**
Historical and ethnopharmacological use of Pyropia yezoensis includes antitumor properties, and the sulfated polysaccharide fraction has been explored in preclinical contexts for antiproliferative activity, though mechanistic data specific to porphyran's antitumor action remain limited in published literature.
**Cardiovascular and Cerebrovascular Support**
Traditional use in East Asian medicine attributes anticardiovascular and anticerebrovascular benefits to dietary consumption of Pyropia yezoensis, with porphyran's lipid-lowering and anti-inflammatory preclinical activities providing a plausible mechanistic basis, pending clinical confirmation.
Origin & History
Natural habitat
Porphyran is a sulfated polysaccharide extracted from Pyropia yezoensis (syn. Porphyra yezoensis), a red marine alga commercially cultivated in coastal waters of China, Japan, and South Korea, where it is widely farmed as nori for culinary use. The alga thrives in cold, nutrient-rich intertidal zones and has been cultivated on suspended nets in estuarine and coastal marine environments for centuries. Porphyran constitutes a significant portion of the cell wall polysaccharide fraction and is isolated via hot water extraction, typically yielding 22–22.3% crude polysaccharide from dried biomass.
“Pyropia yezoensis has been consumed as a traditional marine vegetable—most commonly known as nori—in China, Japan, and South Korea for centuries, where it has been valued not only as a culinary staple in sushi and rice dishes but also as a functional food with documented pharmacological lore encompassing anti-inflammatory, antitumor, antioxidant, immunomodulatory, anticardiovascular, and anticerebrovascular applications. In traditional East Asian medicine, seaweeds including Pyropia species were prescribed as cooling, detoxifying agents for conditions associated with inflammation, phlegm accumulation, and vascular stagnation, with porphyran being a key polysaccharide constituent underlying these attributed effects. Cultivation of Pyropia yezoensis dates to at least the Edo period in Japan, where net-based aquaculture was systematized, enabling large-scale production that persists today across coastal East Asia. The transition from whole-food dietary use to isolated polysaccharide research represents a modern scientific reinterpretation of historical nutritional wisdom, though the bioactive doses achieved through typical dietary intake may differ substantially from those used in laboratory extraction studies.”Traditional Medicine
Scientific Research
All available evidence for porphyran's bioactivities derives exclusively from in vitro cell-based assays and limited preliminary in vivo models (including Drosophila melanogaster larvae for lipid-lowering investigation), with no peer-reviewed human clinical trials identified in the current literature. The highest-quality mechanistic data concern the PPY1 peptide's dose-dependent suppression of NO and ROS in LPS-stimulated RAW 264.7 macrophages at 250–1000 ng/ml (P<0.05), and PPYP's non-cytotoxic lipid-reducing activity in HepG2 cells up to 200 µg/ml, both representing cell culture models with inherent translational limitations. Structural characterization studies employing NMR spectroscopy, gel permeation chromatography (GPC), and MALDI-TOF MS have robustly defined OP145's composition (Mw 2.1 kDa; galactose 68.23%, sulfate 27.76%, 3,6-anhydro-L-galactose 5.20%) and repeating unit architecture, lending credibility to structure-activity relationship hypotheses. Overall, the evidence base is preclinical and early-stage; the ingredient scores low on the translational hierarchy, and independent replication, pharmacokinetic studies, and human trials are necessary before efficacy claims can be substantiated.
Preparation & Dosage
Traditional preparation
**Hot Water Extract (Crude Porphyran)**
32 mL/g yields approximately 22
Optimized extraction at 100°C for 120 minutes with a liquid-to-solid ratio of 29..15–22.3% crude porphyran from dried Pyropia yezoensis biomass; no standardized supplemental dose established.
**Purified Porphyran (PPYP)**
Used in cell-based research at concentrations up to 200 µg/ml; no human dosage equivalent has been derived or validated.
**Oligo-Porphyran (OP145)**
Produced by controlled acid degradation of crude porphyran (dilute H₂SO₄), yielding approximately 36.4% oligo-porphyran (Mw 2.1 kDa, sulfate 27.76%); applied in in vitro antiviral assays; no human dose established.
**PPY1 Peptide**
Derived from enzymatic hydrolysis of Pyropia yezoensis protein; anti-inflammatory activity observed at 250–1000 ng/ml in macrophage cultures; no equivalent human supplemental dose has been defined.
**Dietary (Whole Alga)**
Traditional consumption as dried nori sheets or rehydrated seaweed provides porphyran naturally, but the bioavailable fraction reaching systemic circulation from whole-food consumption has not been quantified.
**Fermented Forms**
Fermentation of Pyropia yezoensis with lactic acid bacteria has been explored for sauce products, which may alter polysaccharide structure and bioavailability; no clinical dosage data available.
**Standardization**
No commercial supplement standardization for porphyran content or molecular weight fraction currently exists in the peer-reviewed literature.
Nutritional Profile
Pyropia yezoensis biomass is nutritionally dense, containing significant protein (approximately 25–47% dry weight, depending on season and cultivation conditions), carbohydrates predominantly as porphyran and other sulfated polysaccharides (~40–50% dry weight), and low fat content (<5% dry weight). The porphyran polysaccharide fraction is characterized by galactose (68.23% in OP145), sulfate esters (27.76%), and 3,6-anhydro-L-galactose (5.20%), along with rhamnose in the native high-molecular-weight form (~151.6 kDa, rhamnose:galactose molar ratio 1:5.3). Micronutrients in the whole alga include iodine, iron, calcium, magnesium, vitamin B12, and vitamin C, though concentrations vary by cultivation conditions and processing methods. Bioavailability of intact high-molecular-weight porphyran (151.6 kDa) from dietary sources is likely limited by gastrointestinal degradation; lower-molecular-weight oligomers such as OP145 (2.1 kDa) may exhibit enhanced mucosal permeability and prebiotic fermentation potential, but formal bioavailability studies in humans are absent.
How It Works
Mechanism of Action
The PPY1 peptide (K-A-Q-A-D, 532 Da) isolated from Pyropia yezoensis protein suppresses LPS-induced inflammatory cascades in macrophages by downregulating pro-inflammatory mediators—including nitric oxide (NO) and reactive oxygen species (ROS)—through inhibition of MAPK (mitogen-activated protein kinase) signaling pathways, thereby reducing downstream cytokine expression without cytotoxic effects up to 1000 ng/ml. Purified porphyran (PPYP) attenuates hepatocellular lipid accumulation in palmitic acid-challenged HepG2 cells, likely through modulation of lipogenic gene expression or fatty acid oxidation pathways, although the precise molecular targets have not been fully delineated in published studies. Oligo-porphyran OP145, composed primarily of →3)-β-D-Gal-(1→4)-α-L-Gal(6S) repeating units with a high sulfate density (27.76%), is proposed to competitively interfere with protein–carbohydrate binding interactions, including SARS-CoV-2 spike protein–ACE2 engagement, consistent with the heparan sulfate mimicry mechanism attributed to sulfated marine polysaccharides. The structural features of porphyran—including β-galactose linkages, sulfate ester groups, and 3,6-anhydro-L-galactose residues—are believed to underpin its multi-target bioactivity by mimicking host glycosaminoglycans and modulating receptor-ligand interactions at cell surfaces.
Clinical Evidence
No human clinical trials investigating porphyran or its derivatives (OP145, PPYP, PPY1) have been reported in the available peer-reviewed literature, placing the entire evidence base at the preclinical stage. In vitro studies demonstrate statistically significant anti-inflammatory effects (P<0.05) of PPY1 peptide in macrophage models and lipid-lowering activity of PPYP in hepatocyte models, but effect sizes have not been translated into clinically meaningful endpoints such as plasma cytokine reduction, liver fat fraction, or cardiovascular risk markers in humans. Preliminary in vivo data from invertebrate models (Drosophila melanogaster) suggest lipid-modulating potential, but these systems differ substantially from human physiology in terms of lipid metabolism, immune signaling, and pharmacokinetics. Confidence in clinical efficacy remains very low; rigorous dose-finding studies, pharmacokinetic profiling in mammals, and randomized controlled trials in human populations are required before any therapeutic or supplemental recommendations can be made.
Safety & Interactions
Based on available preclinical data, porphyran and its derivatives demonstrate a favorable in vitro safety profile: PPYP shows no cytotoxicity in HepG2 hepatocytes at up to 200 µg/ml, and the PPY1 peptide exhibits no cytotoxicity in RAW 264.7 macrophages at up to 1000 ng/ml; however, these cell-based findings cannot be extrapolated to human safety without in vivo toxicology studies. No data on oral acute or chronic toxicity, genotoxicity, or reproductive toxicity in mammals are reported in the current literature, and no maximum tolerated dose or no-observed-adverse-effect level (NOAEL) has been established for any porphyran fraction. Drug interactions have not been studied; given the structural similarity of sulfated polysaccharides to heparin, a theoretical risk of potentiating anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, aspirin, NSAIDs) cannot be excluded and warrants caution. Guidance for use during pregnancy or lactation is entirely absent from the literature, and individuals with shellfish or seaweed allergies, thyroid disorders (due to potential iodine content in whole-alga preparations), or those on anticoagulant therapy should exercise caution and consult a healthcare provider before use.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
PPYPOP145 oligo-porphyranPYP polysaccharidePyropia yezoensisSulfated Polysaccharides (Porphyra umbilicalis)nori sulfated polysaccharidePorphyra yezoensis
Frequently Asked Questions
What is porphyran and where does it come from?
Porphyran is a sulfated polysaccharide extracted from the cell walls of Pyropia yezoensis, the red marine alga used to make nori seaweed sheets in East Asian cuisine. It is a β-type sulfated hetero-rhamno-galactan-pyranose with a native molecular weight of approximately 151.6 kDa, primarily composed of galactose and sulfate groups, and is obtained by hot water extraction at 100°C for 120 minutes, yielding approximately 22% of the dried algal biomass.
What are the anti-inflammatory properties of porphyran?
The primary anti-inflammatory activity associated with Pyropia yezoensis involves the peptide PPY1 (sequence K-A-Q-A-D, 532 Da), derived from algal protein hydrolysis, which dose-dependently suppresses LPS-induced nitric oxide (NO) and reactive oxygen species (ROS) production in RAW 264.7 macrophages at 250–1000 ng/ml (P<0.05) by inhibiting MAPK signaling pathways. The porphyran polysaccharide itself also contributes anti-inflammatory activity attributed to its sulfate ester groups and galactose backbone, though all evidence is currently limited to in vitro cell models with no human clinical trial data available.
Is there any clinical evidence that porphyran works in humans?
Currently, no human clinical trials investigating porphyran or any of its isolated fractions—including OP145, PPYP, or the PPY1 peptide—have been published in the peer-reviewed literature. All available bioactivity data derive from in vitro cell-based assays (macrophage and hepatocyte cultures) and preliminary invertebrate in vivo models, which are early-stage evidence insufficient to establish human efficacy or determine safe supplemental doses.
What is the difference between porphyran and oligo-porphyran (OP145)?
Native porphyran (PYP) has a high molecular weight of approximately 151.6 kDa and is composed of a rhamnose-containing sulfated galactan backbone; oligo-porphyran OP145 is a degraded, purified derivative with a mean molecular weight of just 2.1 kDa, produced by controlled acid hydrolysis with approximately 36.4% yield. OP145 is enriched in →3)-β-D-Gal-(1→4)-α-L-Gal(6S) repeating units, contains 68.23% galactose and 27.76% sulfate, and has been specifically investigated for antiviral properties including inhibition of SARS-CoV-2 spike protein–ACE2 interaction due to its lower molecular weight and higher sulfate density.
Is porphyran safe to take as a supplement?
Preclinical cell culture data indicate that purified porphyran (PPYP) is non-cytotoxic in liver cells up to 200 µg/ml and the PPY1 peptide is non-cytotoxic in macrophages up to 1000 ng/ml, suggesting a reasonable cellular safety margin; however, no mammalian oral toxicology studies, NOAEL determinations, or human safety data have been published. Due to structural similarities to heparin, sulfated porphyran fractions theoretically could potentiate anticoagulant medications, and individuals with seaweed allergies, thyroid conditions, or those taking blood-thinning drugs should consult a physician before supplementing.
How does the PPY1 peptide in porphyran work to reduce inflammation?
The PPY1 peptide (K-A-Q-A-D) derived from Pyropia yezoensis suppresses inflammation by dose-dependently reducing nitric oxide (NO) and reactive oxygen species (ROS) production in immune cells, particularly macrophages. In laboratory studies, this peptide showed significant anti-inflammatory effects at concentrations between 250–1000 ng/ml without causing cell damage. This mechanism suggests porphyran may help modulate the body's inflammatory response at the cellular level.
What is the difference between whole porphyran extract and isolated peptides like PPY1?
Whole porphyran extract from Pyropia yezoensis contains a complex mixture of polysaccharides and proteins, while isolated peptides like PPY1 are single, purified compounds with a defined structure (532 Da). Isolated peptides allow researchers to study specific mechanisms and achieve consistent dosing, but whole extract may provide synergistic benefits from multiple bioactive components. The choice between them depends on whether you prioritize standardization and mechanism specificity or the broader activity profile of the whole ingredient.
Can porphyran supplementation help with oxidative stress-related conditions?
Porphyran contains sulfated galactose and related compounds with demonstrated antioxidant properties that may help protect cells from reactive oxygen species (ROS) damage. The ingredient's ability to reduce ROS production in laboratory models suggests potential benefits for conditions involving oxidative stress, though human clinical evidence remains limited. More research is needed to confirm whether these antioxidant mechanisms translate to measurable health outcomes in people taking porphyran supplements.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w porphyran-pyropia-yezoensis curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
